{"id":"W4248346590","doi":"10.1200/jco.2020.38.15_suppl.5069","title":"First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cohort; Pembrolizumab; Renal cell carcinoma; Internal medicine; Proportional hazards model; Discontinuation; Urology; Clear cell renal cell carcinoma; Oncology; Surgery; Gastroenterology; Cancer; Nuclear medicine; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00206835,0.0004765261,0.0005965679,0.000678236,0.0006290132,0.0009265516,0.0006256805,0.0005277834,0.002211536],"category_scores_gemma":[0.001477094,0.0002930354,0.0007575279,0.000965939,0.0001533365,0.0007786297,0.0005585385,0.0009934603,0.0009744611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007608004,"about_ca_system_score_gemma":0.001226752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006119158,"about_ca_topic_score_gemma":0.009181388,"domain_scores_codex":[0.999396,0.0001230218,0.00006678421,0.0001450571,0.0001821012,0.00008704905],"domain_scores_gemma":[0.9980708,0.0002048236,0.0006609782,0.0002857905,0.0003952082,0.0003824263],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04332386,0.00387672,0.748697,0.001009756,0.003059581,0.0009864222,0.0004283599,0.001643151,0.01642764,0.0004155888,0.04019978,0.1399322],"study_design_scores_gemma":[0.007182909,0.01283317,0.9384832,0.0001935976,0.002072701,0.001465848,0.0001873755,0.001317723,0.002478322,0.0002028241,0.03352384,0.00005850762],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.936501,0.003182187,0.001665763,0.0003525475,0.00009601989,0.001268688,0.05253539,0.0001240581,0.004274406],"genre_scores_gemma":[0.8510654,0.001936916,0.002436934,0.0009977465,0.0001623422,0.0009874417,0.1381447,0.00004949678,0.004219098],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006119158,"threshold_uncertainty_score":0.0121671,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0919111155923545,"score_gpt":0.3896725936607971,"score_spread":0.2977614780684426,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}